Adrenergic modulation of dexketoprofen antinociception in murine formalin orofacial pain

Hugo F. Miranda 1, *, Viviana Noriega 2, 3, Fernando Sierralta 4, Ramón Sotomayor-Zárate 5 and Juan Carlos Prieto 3, 4

1 Neuroscience Department, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
2 Faculty of Medicine, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
3 Cardiovascular Department, Clinical Hospital, Universidad de Chile, Santiago, Chile 
4 Pharmacology Program, ICBM, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
5 Laboratory of Neurochemistry and Neuropharmacology, Faculty of Sciences, Universidad de Valparaiso, Valparaiso, Chile.
 
Research Article
World Journal of Advanced Research and Reviews, 2021, 09(02), 172-178
Article DOI: 10.30574/wjarr.2021.9.2.0063
 
Publication history: 
Received on 20 January 2021; revised on 22 February 2021; accepted on 24 February 2021
 
Abstract: 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in pain whose mechanism of action is the inhibition of cyclooxygenase enzymes (COXs), however, there are evidence of other mechanisms of action, such as the inhibition of substance P, interaction with systems NO, monoaminergic and others. The objective of the present work was to study the participation of a-1 (prazosin) and a-2 (yohimbine) adrenoceptors antagonists in the antinociception of dexketoprofen, the S (+) enantiomer of ketoprofen.  The antinociception evaluation was thru the mice orofacial formalin assay.  Dexketoprofen (DEX) induced a dose-related antinociception 3.40 times more potent in phase I than in phase II. Prazosin i.p. decreased of the antinociception of DEX, 2.01 times in phase I and 4.02 times in phase II. Administered i.t. reduced the antinociception 5.30 times in phase I and 6.20 times in phase II. Yohimbine i.p. induced a reduction of the ED50 of 3.40 times in phase I and 4.50 times in phase II, after i.t. administration the reduction was 5.30 times in phase I and 6.20 times in phase II. The mechanism of antinociception induced by DEX is mediated by the activation of α-1 and α-2 adrenergic receptors at supraspinal and spinal levels.
 
Keywords: 
Adrenergic Modulation; Dexketoprofen; Antinociception; Orofacial Pain; Prazosin; Yohimbine
 
Full text article in PDF: 
Share this